MTMT-ben szereplő publikációk tallózása szerző szerint "Ramaswamy V"

A találatok rendezése: Rendezés: Találatok:

  • Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma 
    Zhukova N; Ramaswamy V; Remke M; Pfaff E; Shih DJ; Martin, DC; Castelo-Branco, P; Baskin, B; Ray, PN; Bouffet, E; von Bueren, AO; Jones, DT; Northcott, PA; Kool, M; Sturm, D; Pugh, TJ; Pomeroy, SL; Cho, YJ; Pietsch, T; Gessi, M; Rutkowski, S; Bognár, László; Klekner, Álmos; Cho, BK; Kim, SK; Wang, KC; Eberhart, CG; Fevre-Montange, M; Fouladi, M; French, PJ; Kros, M; Grajkowska, WA; Gupta, N; Weiss, WA; Hauser, Péter; Jabado, N; Jouvet, A; Jung, S; Kumabe, T; Lach, B; Leonard, JR; Rubin, JB; Liau, LM; Massimi, L; Pollack, IF; Shin, Ra Y; Van, Meir EG; Zitterbart, K; Schuller, U; Hill, RM; Lindsey, JC; Schwalbe, EC; Bailey, S; Ellison, DW; Hawkins, C; Malkin, D; Clifford, SC; Korshunov, A; Pfister, S; Taylor, MD; Tabori, U (2013)
    PURPOSE Reports detailing the prognostic impact of TP53 mutations in medulloblastoma offer conflicting conclusions. We resolve this issue through the inclusion of molecular subgroup profiles. PATIENTS AND METHODS We ...
  • Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas 
    Lassaletta A; Zapotocky M; Mistry M; Ramaswamy V; Honnorat M; Krishnatry R; Stucklin AG; Zhukova N; Arnoldo A; Ryall S; Ling C; McKeown, T; Loukides J; Cruz O; de Torres C; Ho CY; Packer RJ; Tatevossian R; Qaddoumi I; Harreld JH; Dalton JD; Mulcahy-Levy J; Foreman N; Karajannis MA; Wang SY; Snuderl M; Rao AN; Giannini C; Kieran M; Ligon KL; Garre ML; Nozza P; Mascelli S; Raso A; Mueller S; Nicolaides T; Silva K; Perbet R; Vasiljevic A; Conter CF; Frappaz D; Leary S; Crane C; Chan A; Ng HK; Shi ZF; Mao Y; Finch E; Eisenstat D; Wilson B; Carret AS; Hauser, Péter; Sumerauer D; Krskova L; Larouche V; Fleming A; Zelcer S; Jabado N; Rutka JT; Dirks P; Taylor MD; Chen SY; Bartels U; Huang A; Ellison DW; Bouffet E; Hawkins C; Tabori U (2017)
    Purpose BRAF V600E is a potentially highly targetable mutation detected in a subset of pediatric low-grade gliomas (PLGGs). Its biologic and clinical effect within this diverse group of tumors remains unknown. Patients and ...